Device Trial Radar · NCT03150030
Hypoglycaemia and Cardiac Arrhythmias in Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Nov 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Feb 1, 2017
Primary completion
Jan 6, 2020
Study completion Jan 6, 2020
Sponsor
- Lead sponsor
- University Hospital, Gentofte, CopenhagenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 11, 2017
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Twenty-one patients with insulin-treated type 2 diabetes with diabetic complications will be recruited to Part 1 of the study, a three-hour combined hyper- and hypoglycaemic clamp, along with a control group of twenty-one individuals with normal glucose tolerance matched for age, gender, and body mass index. Patients with type 2 diabetes will be scheduled for a three-week run-in period with LR and CGM prior to participation in Part 1. Only patients with a well-functioning loop-recorder and who can comply with CGM will be included. Patients with type 2 diabetes will continue in part 2 of the study, a one year observational study employing CGM and LR and clinical examination after 1, 3, 6, 9, and 12 months and an extended observation period of 2 years employing LR and clinical examination.
Conditions
- Diabetes Mellitus, Type 2
- Arrhythmia, Cardiac
Interventions
Combined hyper- and hypoglycaemic clampOther
During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.
Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)Device
Implantation of a loop-recorder
Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)Device
Monitoring with a continuous glucose monitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Clinically relevant arrhythmiasTime frame: 0-240 min during the combined hyper- and hypoglycaemic clamp
- Part 2: Prevalence of clinically relevant arrhythmias as defined aboveTime frame: Within 12 months
- Part 2: Clinically relevant arrhythmias during hypoglycaemia compared to euglycaemiaTime frame: Within 12 months
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gentofte Hospital
Hellerup, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.